



Cutting-Edge Research in Relapsed and Refractory Multiple Myeloma

Guest Editors:

Dr. Toni Valković

1. Special Hospital "Medico",
Rijeka, Croatia
2. Faculty of Health Studies,
University of Rijeka, Rijeka,
Croatia

Dr. Sandra Bašić-Kinda

Division of Hematology,
Department of Internal Medicine,
University Hospital Centre (UHC)
Zagreb, 10 000 Zagreb, Croatia

Deadline for manuscript
submissions:

15 March 2025

Message from the Guest Editors

Multiple myeloma is one of the most common, incurable, malignant hematological diseases. However, treatment progress tends to be good, demonstrated by extended patient life spans.

In the treatment of relapsed and refractory multiple myeloma, there are great expectations from new immunotherapy modalities, such as bispecific antibodies and CAR T-cell therapy.

The aim of this Special Issue is to present and discuss all biological and clinical aspects of relapsed and refractory multiple myeloma, including epidemiology, diagnostics, antitumor and supportive treatment, and patient monitoring. Although the topic of this Special Issue is relapsed and refractory disease, high-quality and interesting papers dealing with newly diagnosed multiple myeloma will also be considered for publication.

We kindly invite all scientists and clinicians around the world to send their original papers, reviews or mini reviews, case series, and case reports that fit into the theme of this Special Issue and thus contribute to the dissemination of knowledge about this important and frequent hematological malignant disease.





medicina

IMPACT
FACTOR
2.4

Indexed in:
PubMed

CITESCORE
3.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian
University of Health Sciences,
Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Medicina Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/medicina
medicina@mdpi.com